
Tacit Therapeutics: Innovating RNA-targeting treatments for devastating diseases, based in South San Francisco.
Tacit Therapeutics, founded in 2021 and based in South San Francisco, California, is dedicated to developing RNA-targeting treatments for severe diseases. The company's core mission is to repair mutated genes using pre-existing components of human cells, thereby creating non-immunogenic and broadly applicable therapeutic solutions. Their flagship technology, Splicing-Directed Repairâ„¢, aims to fix defective genes while mitigating the risks associated with traditional gene editing methods.
Notable affiliated individuals and investors include leading experts in genetic research and biotechnology venture capitalists. Tacit Therapeutics has achieved significant milestones in advancing RNA repair technologies, positioning itself as a pioneer in the field. The company's innovative approach has the potential to revolutionize the treatment of genetic disorders, making a substantial impact on healthcare and improving patient outcomes globally.

Silence Therapeutics

ReviR Therapeutics
revirtx.com

Locanabio

Nextrna Therapeutics

Wayfinder Biosciences
wayfinderbio.com

Airna
airna.com

Atalanta Therapeutics
atalantatx.com

Remix Therapeutics

Inceptive
inceptive.life

Orbital Therapeutics

ReNAgade Therapeutics

Vicinitas Therapeutics
vicinitastx.com

Rgenta Therapeutics
rgentatx.com

Alltrna
alltrna.com
Rnav8 Bio
Companies similar to Tacit Therapeutics include Silence Therapeutics, ReviR Therapeutics, Locanabio and Nextrna Therapeutics.
Tacit Therapeutics was founded in 2021.
Tacit Therapeutics' headquarters is located in South San Francisco, CA, US.
Tacit Therapeutics' most recent funding round was for $9.5M (USD) in June 2022.
As of Jun 8, 2022, Tacit Therapeutics has raised a total of $9.8M (USD).